1 Warfarin should
be continued for 1 month after cardioversion to allow fo
2 Therapy has
been continued for 1 year in responders.
3 In 15 patients, the drug
was continued for 1 to 14 days while other possible caus
4 r 12 weeks with trastuzumab, and trastuzumab
was continued for 1 year.
5 Treatment with study drug
was continued for 10 days, until the peak white blood ce
6 cin after becoming bacteremic, and treatment
was continued for 10 days.
7 Chest compressions and ventilation
were continued for 10 mins.
8 in lesion area gradually subsided as the WTD
was continued for 12 and 16 weeks.
9 one of the four irbesartan doses, treatment
was continued for 12 weeks and hemodynamic measurements
10 was seen in those patients in whom anakinra
was continued for 12 weeks.
11 by gavage starting at 16 weeks after VC and
was continued for 12 weeks.
12 09, 3 mg/kg/d) was given 1 week after MI and
was continued for 12 weeks.
13 This chemotherapy
was continued for 13 total courses for some patients, wh
14 itiated 11 days after MAb administration and
was continued for 13 weeks in all treated animals.
15 Pacing
was continued for 14 days, and final studies were obtain
16 oped but was reduced when allergen challenge
was continued for 15 days.
17 Drug treatment
was continued for 15 weeks.
18 Therapy
was continued for 176 +/- 117 days, and follow-up includ
19 Maintenance injections
were continued for 18 months or longer.
20 Normothermic perfusion
was continued for 2 hr before in situ cold perfusion wit
21 ot successful, cardiopulmonary resuscitation
was continued for 2 mins before the next defibrillation.
22 the drinking water, and the cholesterol diet
was continued for 2 weeks, at which time the aortas were
23 Study drug
was continued for 24 to 72 hours, and Holter monitoring
24 le after exposure (within 72 hours) and must
be continued for 28 days.
25 gents was started about 1 week after MNU and
was continued for 29 weeks with DFMO.
26 In the remaining 9 dogs, reperfusion
was continued for 3 hours, when MCE was repeated before
27 ed after 1 week as penile rehabilitation and
was continued for 3 months.
28 tinued, but the diet with Gln or Gln placebo
was continued for 3 months.
29 Treatment
was continued for 3 months.
30 ed to active drug, and prospective follow-up
was continued for 3 years.
31 with oral methotrexate and 6-mercaptopurine
was continued for 30 months.
32 Cardiopulmonary resuscitation
was continued for 307 minutes after rescue until venoart
33 The inhaled prostacyclin
was continued for 4 days postoperatively, with no signs
34 quid ventilation or conventional ventilation
was continued for 4 hrs before the animals were killed.
35 The combination antimicrobial therapy
was continued for 42 days and the infection was successf
36 Selective brain cooling
was continued for 45 mins of reperfusion after which pas
37 The scan
was continued for 45 minutes after levodopa intake or un
38 centrations or Ringer solution and perfusion
was continued for 45-60 min.
39 activity; the St John's wort dosing regimen
was continued for 48 hours.
40 Treatment
was continued for 48 weeks if patients had undetectable
41 was started within 24 hrs of enrollment and
was continued for 5 days or until the white blood cell c
42 iven 24 hours after infection, and treatment
was continued for 5 days.
43 began showing signs of growth and treatment
was continued for 5 weeks.
44 Ventilation
was continued for 5.5 hrs.
45 All regimens
were continued for 5 days.
46 hemotherapy or biological therapy and should
be continued for 6-12 months after discontinuation of su
47 ects at higher dosages; (3) treatment should
be continued for 6-12 months to potentially prevent rela
48 Interferon-alpha therapy
was continued for 6 to 9 months in the eight patients ju
49 Both conditions
were continued for 6 weeks.
50 , when exposure of the differentiating cells
was continued for 6days, AC activities then became supra
51 copic plugged catheter, antibiotic treatment
was continued for 7 days.
52 Diets and linseed oil supplementation
were continued for 7 to 12 weeks.
53 red for 2 wk before inoculation of tumor and
was continued for 8 wk, resulting in significant inhibit
54 Treatment was to
be continued for a minimum of 6 months and a maximum of
55 loxifene will gain BMD if the same treatment
is continued for a second year.
56 administered for 1 week prior to lesion and
was continued for a further 2 weeks.
57 eye combinations were reversed and lens wear
was continued for a further 6 months, followed by anothe
58 However, when ethanol treatment
was continued for a longer time, there was a significant
59 Treatment
was continued for a maximum of 16 weeks.
60 Maintenance
was continued for a maximum of four rituximab courses or
61 Therapy
was continued for a maximum of six cycles.
62 of 2 weeks; step-down therapy with an azole
was continued for a median duration of 12 months.
63 Therapy
was continued for a minimum of 48 hours to a maximum of
64 23 BLTx for severe PH, ECMO used during BLTx
was continued for a minimum of 5 days (BLTx-ECMO group).
65 Treatment
was continued for a total of 230 mins.
66 Endocrine therapy
was continued for a total of 5 years, and breast irradia
67 Study interventions
were continued for a median (IQR) of 41 (30-57) days and
68 n, or high-frequency oscillatory ventilation
was continued for an additional 4 hrs before the animals
69 e of the latter experiment), the superfusion
was continued for another 115 min.
70 oved, and iloprost or normal saline infusion
was continued for another 60 mins.
71 he abdomen was manually deflated; monitoring
was continued for another 60 minutes.
72 After device implantation, warfarin
was continued for approximately 45 days, followed by clo
73 Treatment
was continued for as long as the patients derived clinic
74 The simulations
are continued for at least 1s of leukocyte rolling durin
75 tibiotics ordered in critically ill patients
are continued for at least 72 hours in absence of adjudi
76 eatment of GAD with an antidepressant should
be continued for at least 12 months.
77 of disease progression, and treatment should
be continued for at least 12 weeks to ensure adequate dr
78 Treatment
was continued for at least 24 months in patients who sho
79 Of the empiric antibiotics, 333 of 660 (50%)
were continued for at least 72 hours in instances where
80 ated if suppressive antiretroviral treatment
is continued for extremely long periods of time.
81 er completion of local therapy, chemotherapy
was continued for four to 15 cycles, followed by radioth
82 Medications
were continued for four weeks, at which time, the final
83 However, treatment has to
be continued for life because it does not lead to the fu
84 larger decrements in life expectancy if HRT
was continued for life (-0.79 to -1.09 years).
85 ide reverse transcriptase inhibitors (NRTIs)
were continued for median nine days after NNRTI interrup
86 cally treated patients, antibiotic treatment
was continued for more than 24 hours because of acute co
87 ension, the question of how long they should
be continued for prevention of variceal hemorrhage remai
88 b was administered at the end of cycle 1 and
was continued for seven cycles.
89 The drug therapy
was continued for six months post-operatively.
90 eatment began on the same day as surgery and
was continued for the 16-day duration of study.
91 e infusion with iloprost or carrier solution
was continued for the duration of the experiment.
92 as prevented when weekly doses of tacrolimus
were continued for the duration of the experiment rather
93 After 8 weeks, dexamethasone mouthwash could
be continued for up to eight additional weeks at the dis
94 cebo began during week 4 of radiotherapy and
was continued for up to 12 cycles of maintenance chemoth
95 treated for at least 3 months and treatment
was continued for up to 12 months.
96 was interrupted, and Peg-interferon alfa-2a
was continued for up to 12 weeks (the primary end point)
97 60 mg/m(2) once every 4 weeks, and treatment
was continued for up to 12 weeks if no disease progressi
98 Treatment
was continued for up to 42 months until recovery was ach
99 The study drug
was continued for up to 60 days.